Gepotidacin

GSK announces positive headline results from the EAGLE-1 Phase III trial for Gepotidacin in uncomplicated urogenital gonorrhea. Gonorrhoea is the second most common sexually transmitted infection due to the pathogen N. gonorrhoeae. Untreated urogenital gonorrhea can cause serious and permanent health problems, such as pelvic inflammatory disease and infertility.
Gepotidacin is an investigational, first-in-class inhibitor of bacterial topoisomerase. It has a distinct mechanism of action that inhibits bacterial DNA replication by selectively interacting with two key bacterial enzymes, DNA gyrase and topoisomerase IV. Gepotidacin confers activity against most strains of E. coli and S. saprophyticus, and N. gonorrhoeae, including target pathogens resistant to current antibiotics.